Nutritional Supplement Efficacy on Cellular Protection and Skin Health in Generally Healthy Adults

March 2, 2020 updated by: Pharmanex
Healthy skin has been equated with a healthy diet leading to the "inside out" approach to skin health. Since the skin is the barrier to the external world, healthy skin should lead to overall better health. Conversely, the skin derives its nutrition from the internal body requiring the consumption of nutritional supplements for optimal health. This research attempts to examine skin attributes and improved appearance achieved after consumption of a state-of-the-art dietary supplement.

Study Overview

Status

Completed

Conditions

Detailed Description

Subjects will present to the research center and complete an informed consent. They will undergo assessment for inclusion/exclusion criteria, skin examination, BMI calculation, and a brief medical history. Subjects that are found to be appropriate for study entry will undergo an investigator and subject facial evaluation. In addition, they will undergo noninvasive measurements of TEWL, corneometry, skin elasticity, dermspectrophotometry, and assessment with a biophotonic scanner. Facial photography will also be performed. A target site on the right or left sun protected buttock will be selected and will receive 1, 2, and 3 MED of solar simulated radiation.

Subjects will return to the research center 24 hours after irradiation for photography and erythema scaledermospectrophotometer measurement of the irradiated sites and biopsy of the 2 - 3 MED sites. The MED biopsy site will be consistent for each subject, but will be chosen based on the amount of achieved erythema. A 2mm punch biopsy will be taken of the irradiated site and another adjacent nonirradiated site for a total of 2 skin biopsies that will be closed with 5-0 nylon sutures. The biopsy from the nonirradiated site will be processed and shipped as instructed by the sponsor to a laboratory for epigenetic analysis. All subjects will be dispensed the supplement in a white bottle with a research center label along with a compliance diary. Subjects will return in 2 weeks just for suture removal.

At week 4, subjects will undergo an investigator and subject facial evaluation. In addition, they will undergo noninvasive measurements of TEWL, corneometry, skin elasticity, dermspectrophotometry, and assessment with a biophotonic scanner. Subjects will be redispensed study supplements.

Subjects will return to the research facility at week 8 and undergo noninvasive measurements of TEWL, corneometry, skin elasticity, dermspectrophotometry, and assessment with a biophotonic scanner. A target site on the right or left sun protected buttock will be selected and will receive 1, 2, and 3 MED of solar simulated radiation. All supplement bottles and unused product will be collected. Subjects will return to the research center 24 hours after irradiation for photography and erythema scale dermospectrophotometer measurement of the irradiated sites and biopsy of the 2-3 MED sites. The biopsy site will be the same MEDs as the original biopsy site at baseline. A 2mm punch biopsy will be taken of the irradiated site and another adjacent nonirradiated site for a total of 2 skin biopsies that will be closed with 5-0 nylon sutures. The biopsy from the nonirradiated site will be processed and shipped as instructed by the sponsor to a laboratory for epigenetic analysis. All supplement bottles and unused product will be collected. All bottles and unused product will be returned to the sponsor.

Subjects will return to the research center at week 10 for suture removal only.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • High Point, North Carolina, United States, 27262
        • Dermatology Consulting Services

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

36 years to 71 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Individuals must be between 40-75 years of age with no known medical conditions that, in the investigator's opinion, may interfere with study participation.
  • Individuals must present with moderate signs of aging
  • Subject is willing and able to participate in all aspects of the study
  • Individuals must sign informed consent, photo release consent and confidentiality agreement
  • Subject eats 1 or less servings of fatty fish per week
  • Subject has a BMI > 19 and < 30
  • Subjects who have been on a stable dose of chronic use medications for at least 3 months prior to study participation
  • Subjects who, in the opinion of the investigator, are free of any medical condition(s) that might affect study measures

Exclusion Criteria:

  • Subject failure to provide informed consent
  • Individuals that are being treated for cancer or have a history of facial skin cancer on the test areas
  • Individuals with sunburn, moderate to pronounced suntan, even skin tones, tattoos, scars or other disfiguration, dilated vessels or other conditions on the test area that might influence the test results
  • Any disease or condition of the skin that the examining investigator deems inappropriate for participation, including rosacea, eczema, psoriasis, and atopic dermatitis
  • Individuals currently taking medications which in the opinion of the investigators may interfere with the study. This would include but not be limited to routine high dosage use of anti-inflammatory drugs (aspirin, ibuprofen, corticosteroids) immunosuppressive drugs or antihistamine medications (steroid nose drops and/or eye drops are permitted), and insulin, antibiotics or other topical drugs at the test sites.
  • Individuals with uncontrolled metabolic diseases such as diabetes (Type I and II), hypertension, hyperthyroidism or hypothyroidism, severe chronic asthma, immunological disorders such as HIV positive, AIDS and systemic lupus erythematosus or mastectomy for cancer involving removal of lymph nodes
  • Subject is taking supplemental oral dietary/nutritional supplements containing more than 800 IU of vitamin D, 200 mg fish oil, 200 mg krill oil, 2 mg total carotenoids (lycopene, lutein, etc.) and/or 5 mg resveratrol within 30 days prior to study product administration
  • Difficulty in swallowing capsules
  • Women known to be pregnant, nursing or planning to become pregnant
  • Individuals participating in other facial clinical studies
  • Individuals who have routinely used an alpha-hydroxyl-acid (AHA) or a beta-hydroxyl-acid (BHA) containing product within two weeks or Retin-A®, Retin-A Micro®, Renova®, Differin®, Avita®, Tazorac®, or Soriatane® within one month of the study start or have taken Accutane® within one year of the study start. Individuals who have used Retinol in the last six months
  • Individuals with inflammatory acne lesions (i.e., papules, pustules, cysts, nodules) at the test site
  • Individuals who have had chemical peels or dermabrasion within the last six months
  • Individuals with known allergies to fish oil. Individuals currently using topically applied prescription medications where the medication is applied on or near the test site
  • Individuals who have sun tanned (sun or tanning beds) in the nude within the past 1 year
  • Excessive alcohol use (>2 drinks per day)
  • Subject is a current smoker or quit less than 3 years from screening visit
  • History of substance abuse
  • Use of anti-aging treatment skin care products within 30 days of study enrollment and throughout study participation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Nutritional Supplement
Proprietary nutritional supplement
2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cellular protection of the skin
Time Frame: 8 weeks
The primary efficacy endpoint is to determine the effects of a nutritional supplement on cellular protection of the skin induced by UV radiation in generally healthy adults as determined by a reduction in sunburn cell count following supplement ingestion for 8 weeks.
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Skin Health
Time Frame: 8 weeks
The secondary efficacy endpoint is to assess improvement in skin health characteristics in subjects consuming a dietary supplement as evidenced by improvement in the dermatologist investigator overall visual assessment of lines/wrinkles, firmness/elasticity, radiance, skin texture/smoothness, and overall appearance.
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Zoe D Draelos, MD, Dermatology Consulting Services, High Point NC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2015

Primary Completion (Actual)

September 1, 2015

Study Completion (Actual)

September 1, 2015

Study Registration Dates

First Submitted

August 13, 2015

First Submitted That Met QC Criteria

August 13, 2015

First Posted (Estimate)

August 17, 2015

Study Record Updates

Last Update Posted (Actual)

March 4, 2020

Last Update Submitted That Met QC Criteria

March 2, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 15-PHX-0001
  • DCS-50-15 (Other Identifier: Dermatology Consulting Services)

Plan for Individual participant data (IPD)

Study Data/Documents

  1. Clinical Study Report
    Information identifier: DOI: 10.1111/jocd.12295

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Skin Health

Clinical Trials on Nutritional Supplement

Subscribe